Another point with regard to the PASP measurement of the patients in this study was made of tricuspid regurgitant jet. At the same time, the mean tricuspid regurgitant jet velocity was 1.7 ± 0.5 m/s in the patient population. When this value was analyzed, it gave the impression that sufficient flow was not obtained over the tricuspid valve. For this reason, since guidelines recommend to use contrast echocardiography with agitated saline in subjects where the measurement of tricuspid regurgitant jet velocity is difficult (insignificant/mild tricuspid regurgitant), we think this procedure would have enabled them to make a more appropriate evaluation by augmenting Doppler signals significantly [4] , thus giving an opportunity to measure PASP in SCD patients more accurately.
Dear Editor,
We would like to thank Uz et al. for their interest and the comments on our paper [1] . They suggested that they would like to see the baseline characteristics, demographic and other data for the patients and controls in the study in a tabular form. There were no significant differences in these data (including age, body mass index and smoking prevalence) between the patients and the controls. There was, therefore, no need for extra tables and this was indicated in the text. However, the hematological and other laboratory data were significantly different in the two groups as mentioned in the text.
The point about the use of agitated saline contrast echocardiography is well taken. However, this was not part of the design of our study, which was to gain an insight into potential cardiac complications in Kuwaiti sickle cell disease patients who have a generally milder phenotype than seen in North American or African patients [1] . Tricuspid regurgitant jet velocity is one parameter that has been used widely for this purpose, hence its use in our study. Contrast echocardiography may be incorporated into future studies, but the prevalence of cardiac abnormalities appears to be low in our patients.
